Peter Bach, MD, of Memorial Sloan Kettering Cancer Center, summarizes his plenary lecture on drug costs and their effect on the affordability of cancer care worldwide (Plenary Lecture 3).
Jennifer K. Litton, MD, of MD Anderson Cancer Center, and Ann H. Partridge, MD, of the Dana-Farber Cancer Institute, discuss a range of issues for young women with breast cancer, including epidemiologic and biologic differences in younger patients, fertility issues, and pregnancy-associated breast cancer (Poster Discussion 6).
Nikhil Wagle, MD, Dana-Farber Cancer Institute, discusses the genomic sequencing of ER-positive metastatic breast cancer that has become resistant to therapies and the implications for the choice of next therapy, clinical trial eligibility, and novel drug targets (Abstract S1-01).
Lisa A. Carey, MD, of the University of North Carolina, discusses a session she moderated on key data presented at SABCS, and gives her expert views on putting the research data into clinical practice.
Rowan T. Chlebowski, MD, PhD, of the David Geffen School of Medicine at UCLA, discusses findings from the Women’s Health Initiative Dietary Modification study on low-fat diet and breast cancer overall survival (Abstract S5-04).
Mothaffar Rimawi, MD, of the Smith Breast Center at Baylor College of Medicine, discusses phase II findings from a study evaluating pathologic complete response in patients with HR-positive, HER2-positive disease treated with neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab with or without estrogen deprivation (Abstract S3-06).
